Infliximab
Infliximab is a chimeric monoclonal IgG1 antibody that binds with high affinity to both soluble and transmembrane forms of TNF-alpha, neutralizing its inflammatory activity. It is administered via intravenous infusion under medical supervision.
Dosage by Body Weight
Dosage is strictly calculated based on the patient's body weight (typically 3 mg/kg to 5 mg/kg depending on indication). It is administered as an intravenous infusion over at least 2 hours at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks.
- Body Weight
- Below 5 kg
- Dose
- Not routine
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and effectiveness in pediatric patients weighing under 5 kg have not been established.
- Body Weight
- 5-7 kg
- Dose
- 3 mg/kg to 5 mg/kg (Approx. 15 mg to 35 mg)
- Frequency
- Weeks 0, 2, 6, then every 8 weeks
- Tracking Notes
- Administered under strict medical supervision; monitoring for infusion-related reactions is mandatory.
- Body Weight
- 8-10 kg
- Dose
- 3 mg/kg to 5 mg/kg (Approx. 24 mg to 50 mg)
- Frequency
- Weeks 0, 2, 6, then every 8 weeks
- Tracking Notes
- Dose and interval may be adjusted by a specialist based on therapeutic response and serum drug levels.
- Body Weight
- 11-15 kg
- Dose
- 3 mg/kg to 5 mg/kg (Approx. 33 mg to 75 mg)
- Frequency
- Weeks 0, 2, 6, then every 8 weeks
- Tracking Notes
- Typically prescribed for pediatric Crohn's disease or ulcerative colitis in children 6 years and older.
- Body Weight
- 16-20 kg
- Dose
- 3 mg/kg to 5 mg/kg (Approx. 48 mg to 100 mg)
- Frequency
- Weeks 0, 2, 6, then every 8 weeks
- Tracking Notes
- Doses may be increased up to 10 mg/kg in pediatric patients who lose response during maintenance.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine | Use only if prescribed | Safety and effectiveness in pediatric patients weighing under 5 kg have not been established. |
| 5-7 kg | 3 mg/kg to 5 mg/kg (Approx. 15 mg to 35 mg) | Weeks 0, 2, 6, then every 8 weeks | Administered under strict medical supervision; monitoring for infusion-related reactions is mandatory. |
| 8-10 kg | 3 mg/kg to 5 mg/kg (Approx. 24 mg to 50 mg) | Weeks 0, 2, 6, then every 8 weeks | Dose and interval may be adjusted by a specialist based on therapeutic response and serum drug levels. |
| 11-15 kg | 3 mg/kg to 5 mg/kg (Approx. 33 mg to 75 mg) | Weeks 0, 2, 6, then every 8 weeks | Typically prescribed for pediatric Crohn's disease or ulcerative colitis in children 6 years and older. |
| 16-20 kg | 3 mg/kg to 5 mg/kg (Approx. 48 mg to 100 mg) | Weeks 0, 2, 6, then every 8 weeks | Doses may be increased up to 10 mg/kg in pediatric patients who lose response during maintenance. |
Formulation
Purpose
Used to treat moderate to severe inflammatory conditions including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis by blocking TNF-alpha.
Generic Name
InfliximabBranded Drug Names
Infliximab is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.